AnaptysBio Announces FDA Approval of GSK’s Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer Based on AZUR-1 Data
AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli (dostarlimab) for MSI-H/dMMR locally advanced rectal cancer, based on AZUR-1 trial data. The trial showed 68% of patients achieved clinical complete response at 12 months. GSK plans to present full data at ESMO Congress 2026.
How this was made
The 30-second read
Why it matters
The approval creates a new revenue stream for AnaptysBio and may increase GSK's oncology pipeline credibility.
Market read
First‑time FDA approval for a new cancer indication, likely to move AnaptysBio stock and influence the broader immunotherapy sector.
What to watch
Potential reimbursement challenges and the need for commercial rollout with GSK could temper revenue expectations.
Background
AnaptysBio manages royalty collaborations for Jemperli, a PD‑1 inhibitor developed by GSK (Tesaro). The approval expands Jemperli's label to include MSI‑H/dMMR locally advanced rectal cancer.
Ticker impact
AnaptysBio announced FDA approval of Jemperli for MSI-H/dMMR locally advanced rectal cancer.
likely upward pressure as market prices in new indication approval and potential sales uplift.
First report of FDA approval; adds a new, high‑impact indication that can drive royalty revenue.
Market effects
Strengthens the oncology immunotherapy sector and may boost peers with similar PD‑1 antibodies.
Positive for US biotech and pharma stocks, modest effect on European markets where GSK trades.
Adds to global momentum for MSI‑H/dMMR therapies, could influence investor sentiment worldwide.
Counterpoint
If the market has already priced in the approval, the stock may see limited upside.
Key entities
- companyAnaptysBio, Inc.
US‑listed biotech that receives royalties from Jemperli sales.
- companyGlaxoSmithKline plc
Pharma company (Tesaro) that commercializes Jemperli.
